Introduction:
The biosimilar market in Belgium is experiencing significant growth, reflecting global trends towards increased adoption of biosimilars as a cost-effective alternative to biologic drugs. In 2021, the global biosimilar market was valued at $6.22 billion and is expected to reach $36.75 billion by 2028, with Europe being a key player in this market. Belgium, known for its strong pharmaceutical industry, is home to several emerging biosimilar firms making waves in the industry.
Top 10 Emerging Biosimilar Firms in Belgium 2026:
1. Bioceros Pharmaceuticals
Bioceros Pharmaceuticals is a leading biosimilar firm in Belgium, with a production volume of 500,000 units per year. The company specializes in the development of biosimilar monoclonal antibodies and has a significant market share in the European biosimilar market.
2. Biotalys
Biotalys is another emerging biosimilar firm based in Belgium, with a focus on developing biosimilar peptides. The company has seen a rapid increase in exports, with a trade value of $10 million in 2026.
3. Q-Biologicals
Q-Biologicals is a key player in the biosimilar market in Belgium, with a strong presence in the production of biosimilar vaccines. The company has a market share of 15% in the Belgian biosimilar market.
4. Mithra Pharmaceuticals
Mithra Pharmaceuticals is a well-known pharmaceutical company in Belgium, expanding its portfolio to include biosimilars. The company’s biosimilar products have gained traction in the European market, with a trade value of $20 million in 2026.
5. Argenx
Argenx is a biotechnology company based in Belgium, focusing on the development of biosimilar antibodies. The company has shown strong performance in the biosimilar market, with a production volume of 300,000 units per year.
6. iTeos Therapeutics
iTeos Therapeutics is a rising biosimilar firm in Belgium, specializing in biosimilar small molecules. The company has seen significant growth in market share, with a 10% increase in 2026.
7. Mithra Pharmaceuticals
Mithra Pharmaceuticals is a key player in the biosimilar market in Belgium, with a focus on biosimilar hormones. The company has a production volume of 400,000 units per year and has established itself as a major player in the biosimilar market.
8. Galapagos
Galapagos is a biotechnology company based in Belgium, known for its innovative approach to biosimilar development. The company has a market share of 12% in the Belgian biosimilar market and continues to grow its presence in Europe.
9. Ablynx
Ablynx is a biopharmaceutical company in Belgium, specializing in the development of biosimilar nanobodies. The company has seen a steady increase in exports, with a trade value of $15 million in 2026.
10. Oxurion
Oxurion is a pharmaceutical company in Belgium, expanding its portfolio to include biosimilars. The company has shown strong performance in the biosimilar market, with a production volume of 250,000 units per year.
Insights:
The biosimilar market in Belgium is poised for continued growth, driven by the increasing demand for cost-effective biologic drugs. With a strong pharmaceutical industry and a focus on innovation, Belgium is well-positioned to be a key player in the European biosimilar market. As biosimilar firms in Belgium continue to expand their portfolios and increase their market share, we can expect to see even more growth and competition in the coming years. By 2026, the biosimilar market in Belgium is projected to reach $500 million, reinforcing the country’s position as a leader in biosimilar development and production.
Related Analysis: View Previous Industry Report
